Skip to Content
Quarter-End Insights

Health Care: A Strong Run, but Some Stocks Still Look Undervalued

While the sector looks slightly overvalued overall, we still see several stocks that offer attractive valuations across the different industries.

Mentioned: , , , , , , , , ,
  • While we view the health-care sector as slightly overvalued in aggregate, some stocks still look undervalued, including the pharmacy benefit manager (PBM) industry.
  • Mergers and acquisitions continue at a rapid pace, as large conglomerates are looking for growth avenues and opportunities to cut costs, partially through lowering taxes for U.S.-based companies.
  • Drug development in specialty-care areas, including virology and oncology, is increasing the productivity of drug and biotech companies, with several recent launches with very high prices reminding the investment community of the strong moats of large pharmaceutical and biotech firms.
  • Even though several years have passed since the worldwide economic downturn, overall health-care utilization remains tepid, but we see early signs of improvement partly spurred by health-care reform in the U.S.

Over the past few years the valuation of the health-care sector has risen to slightly exceed our fair value estimates in aggregate. However, we still see several stocks that offer attractive valuations across the different industries. In the table below, we highlight a few of our top picks. However, we believe the current environment for health care lends itself to a stock-pickers' market rather than a focus on industries.

In the pharmaceutical and device industries, companies are acquiring and merging to create scale and focus in key strategic areas, in addition to deploying their previously trapped overseas cash, as is the case with the pending acquisition of  Covidien (COV) by  Medtronic (MDT). This deal also showcase the desire to reduce the tax rate of the acquiring firms. However, recent changes in U.S. tax policy will likely slow the torrid pace of M&A seen over the past two years, as the new policy will limit the benefits of reducing the tax rate for U.S. firms merging with an international company. The updated policy likely was the main driver of the collapsed merger between  AbbVie (ABBV) and  Shire PLC (SHPG). Further, the new environment makes it much less likely that  Pfizer (PFE) will return to bid for  AstraZeneca (AZN) following the failed attempt earlier in the year. However, the white knight acquisition of  Allergan (AGN) by  Actavis (ACT) to fend off  Valeant (VRX) looks likely to complete and showcases the importance of scale and cost-cutting between two major health-care companies.  

Turning to innovation in health care, the focus of drug companies is shifting toward specialty-care areas, which should increase drug-development productivity. The pipelines of the major biotech and pharmaceutical companies are focused on smaller patient populations in areas such as immunology, virology, and oncology. We believe these areas offer unmet medical need, which should lead to better approval odds and stronger pricing power. Further, despite treating smaller patient populations, these indications can turn into major blockbusters.  Merck's (MRK) recent approval of Keytruda in melanoma is a good example of a small patient population, but an annual price of about $150,000 should turn the drug into a major commercial success.

Although the economic downturn passed several years ago, health-care utilization remains tepid, but recent signs are pointing to a pickup of the market. Historically, a lag of a couple of years tends to follow a recession before health-care spending returns. However, the magnitude of the recession and increasing cost-sharing with patients has delayed a sharp rebound in health-care use. The increase in U.S. hospital admissions starting in the second quarter suggests a turning point in health-care usage; U.S. health-care reform is likely driving part of the uptick. With the mandated health-care insurance and expanded government insurance in the U.S., more people are seeking out treatment. We expect a continual, gradual increase in demand for health care, but probably not a return to 2007 levels anytime soon.

Top Health-Care Sector Picks

Star Rating Fair Value
Fair Value
Baxter $84 Wide Low $67.20
Elekta SEK 95 Wide Medium  SEK 65.50
Sanofi $59 Wide Medium $41.30
Data as of 12-23-14

 Baxter (BAX)
Although competition is increasing for Advate, Baxter's highly profitable hemophilia A product, we think this diversified firm's competitive advantages remain strong and the stock looks undervalued. We think this diversified health-care firm has earned a wide economic moat, stemming from economies of scale in plasma processing, injectable therapies, and dialysis products. Intangible assets--like Baxter's strong brands, patent protection, and pipeline productivity--also allow the firm to remain remarkably profitable in tough industries. More than 70% of Baxter's sales come from products with market-leading positions, and the safety and quality of its biologic therapies allow it to charge a price premium over competitors.

 Elekta (EKTA) (Sweden)
We believe Elekta is well-positioned in the radiotherapy market, which has tremendous growth potential as improvements in technology, increasing awareness of the clinical benefits, and a favorable cost/benefit proposition should dramatically increase global adoption over the next decade. Further, we feel that Elekta carries a wide moat based on a solid position in a market that is characterized by high barriers to entry, high switching costs, and strong intellectual property. This field has evolved into a duopoly over the past decade with virtually no new entrants, and the main two players (Elekta and  Varian (VAR)) have built durable franchises and are well-positioned for growth.

 Sanofi (SNY)
Despite some weakness in pricing for insulin drugs, we expect Sanofi's key narrow- and wide-moat divisions (emerging markets, diabetes, vaccines, consumer products, rare-disease drugs, and animal health treatments) to continue to post steady gains. Further, based on our view that the investment community underappreciates Sanofi's strong competitive advantages and improving growth profile, we believe Sanofi trades significantly below our fair value estimate. The company’s strengths in patents, but also from branding, cost advantages, and efficient scale areas give it a wide moat that is supported by the majority of Morningstar's moat sources.

More Quarter-End Insights

Damien Conover does not own (actual or beneficial) shares in any of the securities mentioned above. Find out about Morningstar’s editorial policies.